Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) has provided an update on its planned phase 1 clinical human study of AP-188 (dimethyltryptamine or.
This article reviews the essential regulatory considerations surrounding medicines and medical devices in Malta, including clinical trials and marketing authorisations.
This article reviews the essential regulatory considerations surrounding medicines and medical devices in Sweden, including clinical trials and marketing authorisations.